Johns Hopkins Kimmel Cancer Center investigators report they have designed a blood test that accurately detects the presence of advanced breast cancer and also holds promise for precisely monitoring response to cancer treatment.
In experiments with mice, Johns Hopkins Kimmel Cancer Center scientists have identified an enzyme involved in the regulation of immune system T cells that could be a useful target in treating asthma and boosting the effects of certain cancer therapies.
The following announcements are related to awards that have been presented during the American Association for Cancer Research (AACR) Annual Meeting 2014, held in San Diego April 5-9, to researchers at the Johns Hopkins Kimmel Cancer Center.
Research in mice and human cell lines has identified an experimental compound dubbed TTT-3002 as potentially one of the most potent drugs available to block genetic mutations in cancer cells blamed for some forms of treatment-resistant leukemia.
In a series of studies involving 140 American men and women with liver tumors, researchers at Johns Hopkins have used specialized 3-D MRI scans to precisely measure living and dying tumor tissue to quickly show whether highly toxic chemotherapy – delivered directly through a tumor’s blood supply – is working.
An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.
Certain fragments of DNA shed by tumors into the bloodstream can potentially be used to non-invasively screen for early-stage cancers, monitor responses to treatment and help explain why some cancers are resistant to therapies, according to results of an international study led by Johns Hopkins Kimmel Cancer Center investigators.
Investigators at Johns Hopkins report they have developed human induced-pluripotent stem cells (iPSCs) capable of repairing damaged retinal vascular tissue in mice. The stem cells, derived from human umbilical cord-blood and coaxed into an embryonic-like state, were grown without the conventional use of viruses, which can mutate genes and initiate cancers, according to the scientists. Their safer method of growing the cells has drawn increased support among scientists, they say, and paves the way for a stem cell bank of cord-blood derived iPSCs to advance regenerative medicine research.
In laboratory experiments conducted on human cell lines at the Johns Hopkins Kimmel Cancer Center, scientists have shown that people carrying certain mutations in two hereditary cancer genes, BRCA2 and PALB2, may have a higher than usual susceptibility to DNA damage caused by a byproduct of alcohol, called acetaldehyde.
Allegheny Health Network and Johns Hopkins Medicine announced today that they have signed a memorandum of understanding (MOU) to seek to establish a formal affiliation between Allegheny and the Johns Hopkins Kimmel Cancer Center, a National Cancer Institute-designated comprehensive cancer center, for clinical collaborations, medical education, and a broad range of cancer research initiatives. Details of an initial five-year affiliation outlined in the MOU are expected to be finalized within the next few months, officials of the institutions say.
Johns Hopkins scientists say a previously known but little studied chemical compound targets and shuts down a common cancer process. In studies of laboratory-grown human tumor cell lines, the drug disrupted tumor cell division and prevented growth of advanced cancer cells.
Scientists at the Johns Hopkins Kimmel Cancer Center will receive $90 million in new funding as part of a $540 million gift from Ludwig Cancer Research, on behalf of its founder Daniel K. Ludwig, to six U.S. institutions. The new award is among the largest for a single private gift to cancer research.
Johns Hopkins Kimmel Cancer Center investigators have genetically engineered a new mouse that mimics a common form of leukemia in humans. Studying the model could lead to new understanding of the disease, they say.